Evidence map›Paper›PMID 39773062›Full record

ReviewCurrent cardiology reviews2025

The Intersection of Heart Failure and Iron Deficiency Anemia: Diagnostic and Therapeutic Approaches.

Maleesha Bw Thammitage, Naji Moussa, Ali Rezvani, Damandeep Kaur Dhillon, Miryam Lisseth Obando Gamarra, Kanwaraj Singh, Abdul Hawwa, Alejandra Felix Vicente, Sehajpreet Kaur, Kiranmayee Seshasai Nemalapuri and 2 more

Abstract readReview
In one paragraph

Review in Current cardiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maleesha Bw ThammitageAloka Medical Center, Horona, Ratnapura, Sri Lanka.
Naji MoussaDepartment of Cardiology, Richmond Gabriel University, Kingstown, St. Vincent, Caribbean.
Ali RezvaniSchool of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Damandeep Kaur DhillonSaint James School of Medicine, Dallas, TX 75238, USA.
Miryam Lisseth Obando GamarraUniversidad Andina del Cusco, Cusco, Peru.
Kanwaraj SinghMaharishi Markendeshwar Institute of Medical Sciences and Research, Ambala, Haryana, India.
Abdul HawwaSchool of Medicine, St. George's University, Grenada, West Indies.
Alejandra Felix VicenteDepartment of Internal Medicine, Universidad de Sonora, Sonora, Mexico.
Sehajpreet KaurPunjab Institute of Medical Sciences, Jalandhar, Punjab, India.
Kiranmayee Seshasai NemalapuriMassachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA.
Devika PoonwassieDepartment of Internel Medicine, University of West Indies, St. Augustine, Trinidad and Tobago.
Manju RaiDepartment of Medical Biotechnology, Shri Venkateshwara University, Gajraula, Ludhiana, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients. Crucially, addressing IDA in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to side effects. In contrast, intravenous (IV) iron therapy is highly effective in enhancing hematological parameters, functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Compliance remains paramount for positive outcomes with IDA treatment, with oral supplementation being cost-effective and easily accessible. However, parenteral supplementation proves beneficial for patients intolerant to oral therapy. Addressing IDA through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients. This paper consolidates insights into the diagnosis, treatment, impact, pathophysiology, clinical outcomes, research gaps, and future directions concerning IDA in HF patients, drawing on extensive literature to offer a comprehensive understanding of this critical issue.

Indexed as

Anemia, Iron-DeficiencyHeart FailureIronHumansPrognosisQuality of LifeIronclinical outcomesHeart failureindividualized approach.intravenous iron therapyiron deficiency anemiaprognosis

Identifiers

PMID39773062
PMCPMC12172222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.